natgillin/translations-raw huggingface dataset:
Rare: anxiety, nightmares, depression, hallucinations.
Redki: anksioznost, nočne more, depresija, halucinacije.
• certain anti-inflammatory agents (e.g. ibuprofen, naproxen, but not acetylsalicylic acid), if ciprofloxacin is given in very high doses.
• Nekatera protivnetna zdravila (npr. ibuprofen, naproksen, toda ne acetilsalicilna kislina), če se ciprofloksacin daje v zelo velikih odmerkih.
The maximum daily dose is 1200 mg.
Največji dnevni odmerek je 1200 mg.
In this case you should immediately consult your doctor.
V takem primeru se takoj posvetujte z zdravnikom.
For more details regarding some of the side effects please see Section 2, ‘Take special care with Ciprofloxacin Kabi- During or after treatment'.
Za več informacij glede nekaterih neželenih učinkov glejte poglavje 2 »Bodite posebno pozorni pri uporabi zdravila Ciprofloxacin Kabi - med zdravljenjem ali po njem«.
Very rare: increment of amylase/lipase levels.
Zelo redki: povišane vrednosti amilaze/lipaze.
There are however no sufficient clinical data available to draw conclusion about the effectiveness of ciprofloxacin in the treatment of anthrax in humans.
Vendar pa ni na voljo dovolj kliničnih podatkov, da bi lahko sklepali o učinkovitosti ciprofloksacina za zdravljenje antraksa pri človeku.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Upoštevati je treba veljavne smernice glede ustrezne uporabe in predpisovanja antibiotikov.
To maintain the activity of the fluoroquinolone class, clinicians need to implement an evidence-based approach to antimicrobial selection, particularly a strategy in which the most pharmacodynamically potent fluoroquinolone is matched, on an empiric basis when required, to anticipated bacterial pathogens.
Da bi ohranili aktivnost fluorokinolonov, morajo klinični zdravniki pri izbiri antimikrobiotikov uporabiti pristop, ki temelji na dokazih, zlasti pa strategijo, pri kateri se za pričakovane bakterijske patogene uporabi, po potrebi tudi na empirični osnovi, farmakodinamično najbolj močan fluorokinolon.
In this case you should immediately consult your doctor, since you may have a severe inflammation of the large intestine (pseudo membranous colitis).
V takem primeru se takoj posvetujte z zdravnikom, saj imate lahko hudo vnetje debelega črevesa (psevdomembranski kolitis).
Mechanism of resistance:
Mehanizem rezistence:
Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.
Bolniki, ki prejemajo ciprofloksacin morajo biti dobro hidrirani in potrebno se je izogibati prekomerno alkalnemu urinu.
As a result of its mechanism of action, ciprofloxacin does not show cross-resistance with other important, chemically different groups of substances such as beta-lactam antibiotics, aminoglycosides, tetracyclines, macrolides and polypeptides, sulphonamides, trimethoprim and nitrofurantoine.
Zaradi svojega mehanizma delovanja ciprofloksacin ne kaže navzkrižne odpornosti z drugimi pomembnimi, kemično drugačnimi skupinami snovi, npr. betalaktamskimi antibiotiki, aminoglikozidi, tetraciklini, makrolidi in polipeptidi, sulfonamidi, trimetoprimom in nitrofurantoinom.
If exposure to sunlight or UV light is inevitable you should use sun cream to protect yourself.
• Če je izpostavljenost sončni ali ultravijolični svetlobi neizogibna, za zaščito uporabite kremo za sončenje.
• feeling depressed or confused after administration of Ciprofloxacin Kabi.
• Občutek depresije ali zmedenosti po jemanju zdravila Ciprofloxacin Kabi.
Evidence is mounting that suggests a link between inappropriate fluoroquinolone use, development of antimicrobial resistance against the entire fluoroquinolone class, and clinical failure.
Vse več je dokazov, ki nakazujejo na povezavo med neprimerno uporabo fluorokinolona, razvojem odpornosti mikroorganizmov na celoten razred fluorokinolonov in neuspehom kliničnega zdravljenja.
Paediatric patients:
Pediatrični bolniki:
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE, PREDLAGATELJEV, IMETNIKOV DOVOLJENJA ZA PROMET V DRŽAVAH ČLANICAH
Anaphylactic/anaphylactoid reactions can in very rare cases develop into life-threatening shock, sometimes even after the first administration of ciprofloxacin.
Anafilaktične/anafilaktoidne reakcije se lahko v zelo redkih primerih razvijejo v smrtno nevaren šok, včasih celo že po prvi uporabi ciprofloksacina.
If you use one of these medicines together with ciprofloxacin you will be monitored for signs of overdose.
Če katerega od teh zdravil jemljete sočasno s ciprofloksacinom, vas bodo spremljali za znake prevelikega odmerjanja.
As with all other antibiotics, the patient should be monitored during therapy for the development of resistant strains of initially sensitive bacteria, especially P. aeruginosa and S. aureus (see the relevant statements in section 5.1).
Tako kot pri zdravljenju z drugimi antibiotiki je treba bolnika med terapijo nadzirati glede pojava odpornih sevov uvodoma občutljivih bakterij, zlasti P. aeruginosa in S. aureus (glejte zadevne navedbe v poglavju 5.1).
Generally, acute and chronic infections (e.g. osteomyelitis and prostatitis, etc), where the causative organism is known to be sensitive to ciprofloxacin, should be treated for at least three days after the signs and symptoms of the infection have disappeared.
Za akutne in kronične okužbe (tj. osteomielitis in prostatitis, itd.), kjer je znano, da je povzročitelj občutljiv za ciprofloksacin, splošno velja, da jih je treba zdravljenje nadaljevati najmanj tri dni po izginotju znakov in simptomov okužb.
A study on Rhesus-monkeys that were exposed to anthrax by inhalation revealed that 8/9 animals survived the experiment when these animals were treated from 1 day after anthrax exposure with ciprofloxacin twice daily for a period of 30 days.
Študija na opicah Rhesus, izpostavljenih vdihanemu antraksu, je pokazala, da je 8 od 9 živalih poskus preživelo, če so te živali od 1. dne po izpostavljenosti antraksu zdravili s ciprofloksacinom dvakrat na dan 30 dni.
Unless compatibility is proven, the solution for infusion should always be administered separately.
Če združljivost ni dokazana, je treba raztopino za injiciranje vedno uporabljati posebej.
In acute and extreme overdosage, reversible kidney damage is seen.
Pri akutnem in skrajno prevelikem odmerjanju so opazili reverzibilno poškodbo ledvic.
- The applicant submitted in addition to the proposed Summary of Product Characteristics, a proposal for harmonised labelling and package leaflet.
- Vlagatelj je poleg predloga Povzetka glavnih značilnosti zdravila predložil tudi predlog za usklajeno označevanje in Navodila za uporabo.
Management of patients with complicated urinary tract infections (UTIs) currently includes empirical treatment with a broad-spectrum antibiotic (fluoroquinolone), and potential subsequent treatment for 10-14 days based on urine culture and sensitivity.
Zdravljenje bolnikov z zapletenimi okužbami sečil trenutno obsega empirično zdravljenje z antibiotikom širokega spektra (fluorokinolon) in morebitno naknadno, 10 do 14 dni trajajoče zdravljenje, ki je odvisno od urinske kulture ter občutljivosti.
* MRSA are very likely to be resistant to ciprofloxacin and ciprofloxacin should not be used to treat presumed or known MRSA infections unless the organism is known to be susceptible.
*Obstaja velika verjetnost, da je MRSA rezistentna na ciprofloksacin in ciprofloksacin se ne sme uporabljati za zdravljenje domnevnih ali znanih okužb z MRSA razen če je mikroorganizem ocenjen za občutljivega.
The renal clearance occurs through glomerular filtration and active tubular secretion.
Ledvični očistek poteka z glomerulno filtracijo in aktivno tubulnosekrecijo.
The dosage in children with impaired renal and/or hepatic function has not been investigated.
Odmerjanje pri otrocih z okvarjenim delovanjem ledvic in/ali jeter ni raziskano.
• Do not refrigerate or freeze.
• Ne shranjujte v hladilniku ali zamrzujte.
Most frequent side effects affect the stomach and intestine, the nervous system and the skin and connective tissue.
Najpogostejši neželeni učinki prizadenejo želodec in črevo, živčni sistem in kožo ter vezivno tkivo.
• severe and continuous diarrhoea during treatment, possibly with blood and mucus.
• Huda in trajajoča driska med zdravljenjem, lahko s krvjo ali sluzjo.
• methotrexate (used to treat cancer or suppress the immune system).
• Metotreksat (za zdravljenje raka ali zaviranje imunskega sistema).
This may increase the effect of glibenclamide (too low blood sugar level).
To lahko poveča učinek glibenklamida (prenizka koncentracija sladkorja v krvi);
Animal trials have shown that the concurrent administration of very high doses of fluoroquinolones and certain NSAIDs (but not acetylsalicylic acid) may provoke convulsions.
Poskusi na živalih so pokazali, da lahko sočasna uporaba zelo velikih odmerkov fluorokinolonov in nekaterih nesteroidnih protivnetnih zdravil (vendar ne acetilsalicilne kisline) povzroči konvulzije.
Impaired hepatic function: In case of impaired hepatic function it is not necessary to adjust the dosage.
Okvarjeno delovanje jeter: V primeru okvarjenega delovanja jeter odmerka ni potrebno prilagoditi.
No data was presented comparing the efficacy, safety or prevention of bacterial resistance using the 800mg maximum IV dose licensed in the UK and the 1200mg IV ciprofloxacin proposed by the applicant.
Vlagatelj ni predstavil podatkov, ki bi primerjali učinkovitost, varnost ali preprečevanje odpornosti bakterij pri 800 mg največjem intravenskem odmerku, ki so ga odobrili v Združenem kraljestvu, in 1200 mg ciprofloksacina intravensko, ki ga je predlagal vlagatelj.
Ciprofloxacin Kabi cannot be mixed with solutions that are not stable at a pH of approximately 4.
Ciprofloxacina Kabi ne smemo mešati z raztopinami, ki niso stabilne pri pH približno 4.
• known allergic reaction to ciprofloxacin or any of the other ingredients of Ciprofloxacin Kabi or other medicines of the quinolone type
• znana alergijska reakcija na ciprofloksacin ali katero koli sestavino zdravila Ciprofloxacin Kabi ali druga zdravila iz skupine kinolonov,
When undesirable effects on the central nervous system, like dizziness, occur, it is prohibited to drive a vehicle or to operate machines.
Če se pojavijo neželeni učinki na osrednje živčevje, npr. omotica, bolnik ne sme voziti ali upravljati s stroji.
The peak plasma concentration is reached 0.5 - 2 hours after taking 50 - 1000 mg p.o. and varies from 0.3 - 5.9 mg/l.
Največjo koncentracijo v plazmi doseže od 0,5 do 2 uri po peroralni uporabi od 50 do 1000 mg in sega od 0,3 do 5,9 mg/l.
Adverse reactions have been reported in 5-14% of patients receiving ciprofloxacin.
O neželenih učinkih so poročali pri 5-14 % bolnikov, ki so prejemali ciprofloksacin.
increased blood sugar level (hyperglycaemia) Mental (psychiatric) disorders Rare:
zvišana koncentracija sladkorja v krvi (hiperglikemija) Duševne (psihiatrične) motnje Redki:
Please inform your doctor when under treatment with Ciprofloxacin Kabi as the result of this test may be false.
Obvestite zdravnika, da se zdravite z zdravilom Ciprofloxacin Kabi, saj je lahko rezultat tega testa lažen.
However, like a number of other quinolones ciprofloxacin is phototoxic in animals in exposure values relevant to humans.
A tako kot številni drugi kinoloni je tudi ciprofloksacin pri živalih fototoksičen pri izpostavljenostih, ki so pomembne za človeka.
Since the risks for humans are unknown Ciprofloxacin Kabi must not be administered during pregnancy (see section 4.3).
Ker tveganja za človeka niso znana, se Ciprofloxacina Kabi ne sme uporabljati med nosečnostjo (glejte poglavje 4.3).
Since ciprofloxacin is associated with very rare cases of QT prolongation (see section 4.8) caution should be exercised when treating patients at risk for torsade de pointes arrhythmia.
Ker je ciprofloksacin povezan z zelo redkimi primeri QT podaljšanja (glejte poglavje 4.8) je potrebna previdnost pri zdravljenu bolnikov s tveganjem za aritmijo “torsade de pointes”.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
Če se raztopina ne uporabi takoj je za čas shranjevanja raztopine in pogoje shranjevanja odgovoren uporabnik.
It is also effective against Gram-positive organisms, such as staphylococci and streptococci.
Učinkovit je tudi proti grampozitivnim mikroorganizmom, npr. stafilokokom in streptokokom.
Other preclinical effects were observed only at exposures that were sufficiently in excess of the maximum human exposure so that concern for human safety is negligible.
Druge predklinične učinke so opažali samo pri izpostavljenostih, bistveno višjih od največje izpostavljenosti pri človeku.
When symptoms occur, such as yellowing of the skin or whites of the eyes, you should immediately consult your doctor.
Če se pojavijo simptomi, kot je porumenelost kože ali beločnic, se takoj posvetujte z zdravnikom;
The elimination half-life of ciprofloxacin does not change with age.
Eliminacijski razpolovni čas ciprofloksacina se s starostjo ne spreminja.
Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, tacrine, ropinirol, tizanidine).
Ciprofloksacin zavira CYP1A2 in tako lahko zviša serumsko koncentracijo tistih sočasno uporabljenih zdravil, ki se presnavljajo s tem encimom (npr. teofilin, klozapin, takrin, ropinirol, tizanidin).
In steady-state conditions the apparent distribution volume of ciprofloxacin is situated between 1,7 and 2,7 l/kg.
Navidezni volumen porazdelitve ciprofloksacina v stanju dinamičnega ravnovesja je med 1,7 in 2,7 l/kg.
The frequencies of probably and/or possibly drug-related adverse events did not differ significantly between ciprofloxacin-treated patients and the comparator groups.
Pogostost neželenih učinkov, ki so verjetno in/ali morda povezani z zdravili, pri bolniki zdravljenih s ciprofloksacinom ni kazala znatnih odstopanj glede na primerjalne skupine.
administration of 200 mg the plasma concentration is still higher than the MIC values of the majority of clinically relevant pathogens (approximately 0.1 µg/ml).
Dvanajst ur po intravenski uporabi 200 mg je koncentracija v plazmi še vedno večja od MIK za večino klinično pomembnih patogenov (približno 0,1 µg/ml).
Pharmacotherapeutic group: Quinolone antibacterials (ATC code: J01MA02) Mode of action:
Farmakoterapevtska skupina: kinolinske protimikrobne učinkovine (oznaka ATC: J01MA02).
The ciprofloxacin concentration in the sputum consists of 50-70% of the serum concentration.
Koncentracija ciprofloksacina v sputumu je od 50 do 70 % tiste v serumu.
Use during pregnancy is contraindicated.
Uporaba ciprofloksacina med nosečnostjo je kontraindicirana.
The applicant has submitted evidence demonstrating the historical development of ciprofloxacin resistance and the decreasing margin between antibiotic resistance and the MIC.
Vlagatelj je predložil dokaze, ki so pokazali zgodovinski razvoj odpornosti na ciprofloksacin in manjšajočo se razliko med odpornostjo na antibiotike in minimalno zaviralno koncentracijo (MIC).
Because ciprofloxacin has some activity against Mycobacerium tuberculosis, false-negative cultures may occur when the specimens are obtained during ciprofloxacin treatment.
Ker ima ciprofloksacin nekaj aktivnosti proti Mycobacterium tuberculosis, se lahko pojavi lažno negativna kultura pri odvzetih vzorcih med zdravljenjem s ciprofloksacinom.
In doing so the applicant/ MAH should discuss the data in relation to complicated and uncomplicated, upper and lower urinary tract infections.
Pri tem bi moral vlagatelj/imetnik dovoljenja za promet podatke obravnavati tudi glede na zapletene in nezapletene oblike okužb ter okužb zgornjih in spodnjih sečil.
Ciprofloxacin Kabi should be administered via a short-term intravenous infusion (infusion into a vein) over 60 minutes.
Ciprofloxacin Kabi je treba dajati kot kratkotrajno intravensko infuzijo (infuzija v veno) v času 60 minut.
When used simultaneously, ciprofloxacin may, in certain cases, increase the effect of glibenclamide (hypoglycaemia).
Sočasno uporabljeni ciprofloksacin lahko v določenih primerih poveča učinek glibenklamida (hipoglikemija).
Ciprofloxacin Kabi has minor or moderate influence on the ability to drive and use machines.
Ciprofloxacin Kabi ima blag ali zmeren vpliv na sposobnost vožnje in upravljanja s stroji.
Fresenius Kabi España S.A.c./ Marina 16-18, planta 17,E-08005
Fresenius Kabi España S.A.c./ Marina 16-18, planta 17,E-08005 Barcelona, Španija
The following infections may be treated intravenously (via the blood) with Ciprofloxacin Kabi:
Pri naslednjih okužbah pride v poštev intravensko (preko krvi) zdravljenje s Ciprofloxacinom Kabi:
The elimination half-life of ciprofloxacin after single or multiple oral dosage is between 3,4 and 6,9 hours.
Eliminacijski razpolovni čas ciprofloksacina po posamičnem ali večkratnem peroralnem odmerjanju je med 3,4 in 6,9 ure.
Fresenius Kabi Pharma Portugal Lda., Avenida do Forte 3, Edifício Suécia IV, Piso 3, 2794-039
Fresenius Kabi Pharma Portugal Lda., Avenida do Forte 3, Edifício Suécia IV, Piso 3, 2794-039 Carnaxide, Portugalska
The phototoxic, photomutagenic and photocarcinogenic potential of ciprofloxacin is comparable to that of other gyrase inhibitors.
Fototoksični, fotomutageni in fotokancerogeni potencial ciprofloksacina je primerljiv tistemu pri drugih zaviralcih giraze.
• temporary pain and inflammation of the tendons, in particular of the Achilles tendon.
• Začasna bolečina in vnetje kit, predvsem Ahilove kite.
Any unused solution and the bag should be adequately disposed of, in accordance with local requirements.
Neuporabljeno raztopino in vrečko je potrebno odstraniti v skladu z lokalnimi predpisi.
Development of resistance to ciprofloxacin and other fluoroquinolones has been observed in staphylococci, especially methicillinresistant S. aureus, P. aeruginosa, E.coli and E. faecalis (see the sensitivity table).
Pojav odpornosti proti ciprofloksacinu in drugim fluorokinolonom so zabeležili pri stafilokokih, zlasti za meticilin odporne S. aureus, P. aeruginosa, E. coli in E. faecalis (glejte desni stolpec v tabeli občutljivosti).
demonstrated clinical efficacy of 93% and bacterial eradication of 89%, but this was for the treatment of uncomplicated UTI (3) and efficacy of 91% (n=23) without development of resistance (2).
Dve raziskavi peroralnih 100 mg odmerkov dvakrat dnevno sta pokazali 93 % klinično učinkovitost in 89 % eradikacijo bakterij, vendar le pri zdravljenju nezapletenih okužb sečil (3), in 91 % učinkovitost (n=23) brez pojava odpornosti (2).
Oral anticoagulants (e.g. warfarin)
Peroralni antikoagulanti (tj. varfarin)
At haemodialysis or peritoneal dialysis only a modest amount of ciprofloxacin (less than 10%) is eliminated.
S hemodializo ali peritonealno dializo se izloči le malo (manj kot 10 %) ciprofloksacina.
The total body clearance of ciprofloxacin is independent of the dose and remains unchanged in case of multiple administration.
Celotni telesni očistek ciprofloksacina ni odvisen od odmerka in se v primeru večkratne uporabe ne spremeni.
Ask your doctor or pharmacist for advice before taking any medicine.
Posvetujete se z zdravnikom ali farmacevtom, preden vzamete katerokoli zdravilo.
The ciprofloxacin level in the blood can be increased.
Koncentracija ciprofloksacina v krvi se lahko zviša;
As with other fluoroquinolones, specific undesirable effects with regard to the central nervous system must be taken into account when using Ciprofloxacin Kabi.
Tako kot pri drugih fluorokinolonih je treba tudi med uporabo Ciprofloxacina Kabi upoštevati neželene učinke na osrednje živčevje.
Due to the higher plasma levels in the elderly it is advisable to administer a doses based on creatinine clearance and severity of disease.
Ker je koncentracija v plazmi pri starejših višja, je tem bolnikom priporočljivo dati odmerek prilagojen glede na očistek kreatinina in resnost bolezni.
The renal clearance constitutes 60%-70% of the total body clearance and is approximately 3 times higher than the creatinine clearance.
Na račun ledvičnega očistka gre od 60 do 70 % celotnega telesnega očistka in je približno 3
You must NOT be given Ciprofloxacin Kabi in the following cases:
Ne uporabljajte zdravila Ciprofloxacin Kabi v naslednjih primerih:
Commonly susceptible species Gram-positive species Bacillus anthracis Gram-negative aerobe species Citrobacter spp.
Pogosto občutljive vrste Grampozitivne vrste Bacillus anthracis Gramnegativne aerobne vrste Citrobacter spp.
Ciprofloxacin has a rapid bactericidal effect, both in the growth phase and in the rest phase.
Ciprofloksacin ima hiter baktericiden učinek, tako v fazi rasti kot v fazi mirovanja.
Ciprofloxacin can exacerbate the symptoms of this disease.
Ciprofloksacin lahko poslabša simptome te bolezni.
three times daily as a maximum dose, a superior prevention of antibiotic resistance without a significant increase in adverse reactions in serious and life-threatening infections of other organ systems, there is no reason to conclude that this favourable risk/benefit profile would differ significantly in the treatment of complicated UTIs.
- Ni razloga, da bi na podlagi objavljenih podatkov, ki so za predlagani najvišji odmerek 400 mg intravensko trikrat dnevno pokazali prednosti pri preprečevanju antibiotične odpornosti brez znatnega povečanja neželenih učinkov pri resnih in življenjsko nevarnih okužbah drugih organskih sistemov, zaključili, da bo ta profil tveganj/koristi znatno odstopal od tistega pri zdravljenju zapletenih okužb sečil.
Rare: syncope (fainting), vasodilation (heat stress).
Redki: sinkopa (omedlevica), vazodilatacija (vročinski stres).
In very rare cases ventricular arrhythmia, QT interval prolongation and torsades de pointes have been reported.
V zelo redkih primerih so poročali o ventrikularni aritmiji, podaljšanju QT intervala in “torsades de pointes”.
Very rare: erythema nodosum, erythema multiforme (minor), Stevens-Johnson syndrome, epidermal necrolysis (Lyell Syndrome).
Zelo redki: nodozni eritem, multiformni eritem (minor), Stevens-Johnsonov sindrom, epidermalna nekroliza (Lyellov sindrom).
• bone infections.
• okužbah kosti
The interaction between theophylline and ciprofloxacin is potentially life-threatening.
Interakcija teofilina in ciprofloksacina je potencialno smtno nevarna.
Photosensibility:
Fotosenzibilnost:
The following indications can be considered for treatment with Ciprofloxacin Kabi when oral therapy is not possible or not reliable: - complicated urinary tract infections - infections of the lower respiratory tract including pneumonia caused by aerobic gram-negative bacteria, in case of Streptococcus pneumoniae infections ciprofloxacin is not the substance of first choice.
Zdravljenje s Ciprofloxacinom Kabi pride v poštev pri naslednjih indikacijah, če peroralno zdravljenje ni mogoče ali ni zanesljivo: - zapletenih okužbah sečil, - okužbe spodnjih dihal, vključno s pljučnicami, ki jih povzročajo aerobne gramnegativne bakterije; v primeru okužb s Streptococcus pneumoniae, ciprofloksacin ni zdravilo prve izbire.
Ciprofloxacin, like other quinolones, may enhance the effect of coumarin derivates including warfarin.
Ciprofloksacin tako kot ostali kinoloni lahko poveča učinek kumarinskih derivatov vključno z varfarinom.
Due to the risk of arthropathy and other potentially severe toxicity in the infant, ciprofloxacin is contraindicated during lactation (see section 4.3).
Zaradi tveganja za artropatijo in druge potencialno hude toksične učinke pri otroku je dojenje med zdravljenjem s ciprofloksacinom kontraindicirano (glejte poglavje 4.3).
Concentrations in pulmonary tissue, gynaecological tissue and prostate tissue and fluid were also significantly higher than the serum concentration.
Tudi koncentracije v pljučnem tkivu, ginekološkem tkivu, tkivu prostate in prostatični tekočini so bile pomembno višje od koncentracije v serumu.
Musculoskeletal system:
Mišično-skeletni sistem: